Pemetrexed acid

We are Pemetrexed acid CAS:137281-39-1 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: Pemetrexed acid
CAS.NO: 137281-39-1
Synonyms:
4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoic acid
4-[2-(2-Amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoic Acid
4-(2-(2-Amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzoic acid
Pemetrexed disodium intermediate

Molecular Formula:C15H14N4O3
Molecular Weight:298.29700

Physical and Chemical Properties:
Density: 1.559 g / cm3
Boiling point: 609.183ºC at 760 mmHg
Melting point:> 270ºC (dec.)
Flash point: 322.223ºC
Refractive index: 1.746

Specification:
Appearance:Off-white to pink powder
Purity:≥98%
Water(k.f):<0.5%
Sulphate Ash:<0.1%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Pemetrexed disodium CAS:150399-23-8

Related News: The pharmaceutical industry is related to the national economy and the people’s livelihood. The entire upstream and downstream areas involve all aspects of the national economy. Our government has a long-term direct or indirect policy preference for this.89466-08-0 Catalent’s clinical supply network includes nine cGMP-certified clinical packaging facilities across North America, Europe and Asia, and more than 50 strategically-located depots around the world, providing local and regional options for clinical storage, distribution, expiry update and relabeling services, and clinical returns management.1441673-92-2 Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. 2-fluoro-4-yodo-5-picolina CAS:153034-94-7 Exceeding impurities in the drug substance may cause the product and its preparation to be recalled. The company receives an FDA warning letter or a CEP certificate suspension, which in turn will cause customer compensation, product recall costs, and asset impairment losses to affect the company’s performance.Therefore, the R & D capabilities and registration capabilities of API companies have become the core factors of competition.